Takeda Pharmaceutical (TAK) said Monday it received US Food and Drug Administration approval for Gammagard Liquid erc, a ready-to-use liquid immunoglobulin therapy for the treatment of primary immunodeficiency in patients aged two and older.

Takeda said US commercialization is expected in 2026, followed by a European Union launch by 2027, where the therapy is approved.

The company said it will discontinue manufacturing of its older freeze-dried formulation Gammagard s/d by the end of 2027 due to supply limitations.

Shares of Takeda were up past 1% in recent premarket activity.